ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. a privately-held, clinical-stage immunotherapy company, today announced positive preclinical results for its human Ad5 vaccine candidate that contains both the spike (S) and nucleocapsid (N) SARS-CoV-2 proteins (hAd5 S + N) for preventing COVID-19. The results were published in bioRxiv (“A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T Cell and Neutralizing Antibody Responses”).